BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
REDWOOD CITY, Calif., May 01, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8th, 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Matthew Beck
Solebury Trout
[email protected]
(646) 378-2933
